安非他酮对抑郁症、注意力缺陷多动障碍和戒烟的介导作用。

IF 2 Q3 PSYCHOLOGY, CLINICAL
Health Psychology Research Pub Date : 2023-07-01 eCollection Date: 2023-01-01 DOI:10.52965/001c.81043
Austin Clark, Brendan Tate, Bretton Urban, Ryan Schroeder, Sonja Gennuso, Shahab Ahmadzadeh, David McGregor, Brook Girma, Sahar Shekoohi, Alan D Kaye
{"title":"安非他酮对抑郁症、注意力缺陷多动障碍和戒烟的介导作用。","authors":"Austin Clark, Brendan Tate, Bretton Urban, Ryan Schroeder, Sonja Gennuso, Shahab Ahmadzadeh, David McGregor, Brook Girma, Sahar Shekoohi, Alan D Kaye","doi":"10.52965/001c.81043","DOIUrl":null,"url":null,"abstract":"<p><p>Bupropion had been in use since the late 1980s as an unconventional treatment for depression. Unlike other antidepressants, bupropion has no serotonergic activity and inhibits the reuptake of norepinephrine and dopamine. The drug has been used to treat depression, Attention Deficit Hyperactivity Disorder (ADHD), and smoking cessation. This investigation reviews the pharmacokinetic and pharmacodynamic effects of bupropion and its mechanisms of action and interactions with other drugs. We evaluated the efficacy of major on and off-label uses of bupropion, focusing on the indications, benefits, and adverse effects. Our review demonstrates that bupropion is superior to placebo and non-inferior to SSRIs such as escitalopram in treating major depressive disorder. More research is needed to determine positive patient-centered outcomes such as increases in quality of life. In the case of ADHD, the evidence for efficacy is mixed with poorly conducted randomized clinical trials, small sample sizes, and a lack of long-term assessments. The same is true in the case of bipolar disorder in which there is still limited and controversial data available on bupropion's safety and efficacy. In the case of smoking cessation, bupropion is found to be an effective anti-smoking drug with synergistic benefits when used as a combination therapy. We conclude that bupropion has the potential to provide benefit for a subset of patients who do not tolerate other typical antidepressants or anti-smoking therapies or for those whose treatment goals align with bupropion's unique side effect profile, such as smokers who wish to quit and lose weight. Additional research is needed to determine the drug's full clinical potential, particularly in the areas of adolescent depression and combination therapy with varenicline or dextromethorphan. Clinicians should use this review to understand the varied uses of the drug and identify the situations and patient populations in which bupropion can lend its greatest benefit.</p>","PeriodicalId":51865,"journal":{"name":"Health Psychology Research","volume":"11 ","pages":"81043"},"PeriodicalIF":2.0000,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10317506/pdf/healthpsychologyresearch_2023_11_81043.pdf","citationCount":"0","resultStr":"{\"title\":\"Bupropion Mediated Effects on Depression, Attention Deficit Hyperactivity Disorder, and Smoking Cessation.\",\"authors\":\"Austin Clark, Brendan Tate, Bretton Urban, Ryan Schroeder, Sonja Gennuso, Shahab Ahmadzadeh, David McGregor, Brook Girma, Sahar Shekoohi, Alan D Kaye\",\"doi\":\"10.52965/001c.81043\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Bupropion had been in use since the late 1980s as an unconventional treatment for depression. Unlike other antidepressants, bupropion has no serotonergic activity and inhibits the reuptake of norepinephrine and dopamine. The drug has been used to treat depression, Attention Deficit Hyperactivity Disorder (ADHD), and smoking cessation. This investigation reviews the pharmacokinetic and pharmacodynamic effects of bupropion and its mechanisms of action and interactions with other drugs. We evaluated the efficacy of major on and off-label uses of bupropion, focusing on the indications, benefits, and adverse effects. Our review demonstrates that bupropion is superior to placebo and non-inferior to SSRIs such as escitalopram in treating major depressive disorder. More research is needed to determine positive patient-centered outcomes such as increases in quality of life. In the case of ADHD, the evidence for efficacy is mixed with poorly conducted randomized clinical trials, small sample sizes, and a lack of long-term assessments. The same is true in the case of bipolar disorder in which there is still limited and controversial data available on bupropion's safety and efficacy. In the case of smoking cessation, bupropion is found to be an effective anti-smoking drug with synergistic benefits when used as a combination therapy. We conclude that bupropion has the potential to provide benefit for a subset of patients who do not tolerate other typical antidepressants or anti-smoking therapies or for those whose treatment goals align with bupropion's unique side effect profile, such as smokers who wish to quit and lose weight. Additional research is needed to determine the drug's full clinical potential, particularly in the areas of adolescent depression and combination therapy with varenicline or dextromethorphan. Clinicians should use this review to understand the varied uses of the drug and identify the situations and patient populations in which bupropion can lend its greatest benefit.</p>\",\"PeriodicalId\":51865,\"journal\":{\"name\":\"Health Psychology Research\",\"volume\":\"11 \",\"pages\":\"81043\"},\"PeriodicalIF\":2.0000,\"publicationDate\":\"2023-07-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10317506/pdf/healthpsychologyresearch_2023_11_81043.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Health Psychology Research\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.52965/001c.81043\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2023/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q3\",\"JCRName\":\"PSYCHOLOGY, CLINICAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Health Psychology Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.52965/001c.81043","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"PSYCHOLOGY, CLINICAL","Score":null,"Total":0}
引用次数: 0

摘要

安非他酮作为一种治疗抑郁症的非常规药物,自 20 世纪 80 年代末开始使用。与其他抗抑郁药不同,安非他酮没有血清素能活性,但能抑制去甲肾上腺素和多巴胺的再摄取。该药物已被用于治疗抑郁症、注意力缺陷多动障碍(ADHD)和戒烟。本研究回顾了安非他酮的药代动力学和药效学效应及其作用机制和与其他药物的相互作用。我们评估了安非他酮主要标签内和标签外用途的疗效,重点关注其适应症、益处和不良反应。我们的研究表明,在治疗重度抑郁障碍方面,安非他酮优于安慰剂,也不劣于艾司西酞普兰等 SSRIs。还需要更多的研究来确定以患者为中心的积极疗效,如生活质量的提高。就多动症而言,由于随机临床试验开展得不够充分、样本量较小且缺乏长期评估,因此疗效证据参差不齐。双相情感障碍的情况也是如此,目前关于安非他酮安全性和有效性的数据仍然有限且存在争议。在戒烟方面,我们发现安非他酮是一种有效的戒烟药物,在作为联合疗法使用时具有协同作用。我们的结论是,对于那些不能耐受其他典型抗抑郁药或禁烟疗法的患者,或那些治疗目标与安非他酮独特的副作用特征相一致的患者,如希望戒烟和减肥的吸烟者,安非他酮有可能为他们带来益处。还需要进行更多的研究来确定该药物的全部临床潜力,尤其是在青少年抑郁症以及与伐尼克兰或右美沙芬联合治疗方面。临床医生应通过本综述了解该药物的各种用途,并确定安非他酮在哪些情况下和哪些患者群体中能发挥最大疗效。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Bupropion Mediated Effects on Depression, Attention Deficit Hyperactivity Disorder, and Smoking Cessation.

Bupropion had been in use since the late 1980s as an unconventional treatment for depression. Unlike other antidepressants, bupropion has no serotonergic activity and inhibits the reuptake of norepinephrine and dopamine. The drug has been used to treat depression, Attention Deficit Hyperactivity Disorder (ADHD), and smoking cessation. This investigation reviews the pharmacokinetic and pharmacodynamic effects of bupropion and its mechanisms of action and interactions with other drugs. We evaluated the efficacy of major on and off-label uses of bupropion, focusing on the indications, benefits, and adverse effects. Our review demonstrates that bupropion is superior to placebo and non-inferior to SSRIs such as escitalopram in treating major depressive disorder. More research is needed to determine positive patient-centered outcomes such as increases in quality of life. In the case of ADHD, the evidence for efficacy is mixed with poorly conducted randomized clinical trials, small sample sizes, and a lack of long-term assessments. The same is true in the case of bipolar disorder in which there is still limited and controversial data available on bupropion's safety and efficacy. In the case of smoking cessation, bupropion is found to be an effective anti-smoking drug with synergistic benefits when used as a combination therapy. We conclude that bupropion has the potential to provide benefit for a subset of patients who do not tolerate other typical antidepressants or anti-smoking therapies or for those whose treatment goals align with bupropion's unique side effect profile, such as smokers who wish to quit and lose weight. Additional research is needed to determine the drug's full clinical potential, particularly in the areas of adolescent depression and combination therapy with varenicline or dextromethorphan. Clinicians should use this review to understand the varied uses of the drug and identify the situations and patient populations in which bupropion can lend its greatest benefit.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Health Psychology Research
Health Psychology Research PSYCHOLOGY, CLINICAL-
CiteScore
2.90
自引率
0.00%
发文量
63
审稿时长
15 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信